FENC logo

FENC
Fennec Pharmaceuticals Inc

1,319
Mkt Cap
$201.77M
Volume
203,472.00
52W High
$9.92
52W Low
$4.68
PE Ratio
-17.18
FENC Fundamentals
Price
$5.91
Prev Close
$6.51
Open
$6.46
50D MA
$7.82
Beta
0.89
Avg. Volume
117,699.44
EPS (Annual)
-$0.3409
P/B
5.75
Rev/Employee
$1.28M
$184.20
Loading...
Loading...
News
all
press releases
Fennec Pharmaceuticals (TSE:FRX) Stock Passes Below 50-Day Moving Average - Should You Sell?
Fennec Pharmaceuticals (TSE:FRX) Shares Pass Below 50-Day Moving Average - Here's Why...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Adherex Technologies (FENC) to Release Earnings on Wednesday
Adherex Technologies (NASDAQ:FENC) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 1. (View Earnings Report at...
MarketBeat·5d ago
News Placeholder
Adherex Technologies Q4 Earnings Call Highlights
Fennec Pharmaceuticals reported record commercial growth for PEDMARK during its fourth quarter and full year 2025 earnings call, highlighting expanding adoption in both new and existing accounts...
MarketBeat·5d ago
News Placeholder
Adherex Technologies (NASDAQ:FENC) Announces Earnings Results
Adherex Technologies (NASDAQ:FENC - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.18). The business had revenue of $13.78 million during the quarter, compared to analyst...
MarketBeat·5d ago
News Placeholder
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of -540.00% and -7.94%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.read more...
Benzinga·6d ago
News Placeholder
Pelthos Therapeutics Inc. (PTHS) Reports Q4 Loss, Tops Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +28.35% and +3.78%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below 50 Day Moving Average - Time to Sell?
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average - Here's What Happened...
MarketBeat·10d ago
News Placeholder
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -7.14% and +81.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Adherex Technologies (NASDAQ:FENC) Cut to Buy at Wall Street Zen
Wall Street Zen cut Adherex Technologies from a "strong-buy" rating to a "buy" rating in a research report on Saturday...
MarketBeat·16d ago
<
1
2
...
>

Latest FENC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.